Biotech Sector Hits New Highs On “FED Rally”: ALKS, ASTX, IBB, VPHM
"Yellen" Effect Boosts Markets-FED Policies Clarified With Larry Summers dropping out as a likely candidate for FED Chairman the market may be assured of a continuation of current FED policy. The market sees no surprises in Janet Yellen who is a frontrunner, as she is current Vice Chairman and...
Mixed Tape in Biotech with Several Rayno Winners: ARRY, BIIB, ILMN, RGDX
NASDAQ Struggling As AAPL Down 5%--IBB ($205.36) off 0.4% Near All Time High of $207.78 The market is trying to continue its resilience since the hits on Syria were postponed pending Russian efforts with Assad. The 10 Year Treasury had an A+ offering at 2.94%.This is the highest auction yield...
Money Talks, Stocks Run, Don’t Walk and Biotech is Up 1.4% Update 1 ASTX up 23%
M&A Moves Down the Food Chain: Otsuka to Buy Astex for ~$900M Astex Pharmaceuticals (ASTX $8.22) has been on our focus list since 12/27/11 at $1.63 and today the stock is up 23% on buy-out news as Otsuka seeks cancer drug pipeline. Coming soon, a comparison of mid-cap biopharma stocks....
Are Biotech M&A Premiums Already Built-In? Valuations Do Matter.
(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A. The recent acquisition of...
Stocks Snap-Back After Sell-Off: NASDAQ Up 0.55%, ASTX Soars
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many "undertoads" remain such as weak economic data, taper talk, Q4 earnings and a slowdown in...